/REUN.TO
REUN.TO Stock - Reunion Neuroscience Inc.
Healthcare|BiotechnologyTSX
$1.42-2.74%
$0.04 (-2.74%) • Aug 2
47
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.48
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.56
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for REUN.TO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.41 – $1.43
TARGET (TP)$1.63
STOP LOSS$1.31
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.20
52W High$9.44
52W Low$0.83
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | N/A | $4.86M | $960,895 | $1,000 |
| Gross Profit | N/A | $-4,290,107 | $-583,433 | $-8,403 |
| Gross Margin | N/A | -88.3% | -60.7% | -840.3% |
| Operating Income | $-20,374,630 | $-52,599,634 | $-18,977,607 | $-3,272,177 |
| Net Income | $-48,492,996 | $-54,691,130 | $-23,117,607 | $-2,628,324 |
| Net Margin | N/A | -1125.3% | -2405.8% | -262832.4% |
| EPS | $-4.17 | $-4.74 | $-3.50 | $-0.35 |
Company Overview
Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
REUN.TOBeat Rate
20%
Last 10 quarters
Avg Surprise
-68.2%
EPS vs Estimate
Beats / Misses
2/8
Last 12 quarters
Latest EPS
$-0.45
Q2 2023
EPS Surprise History
Q2 22
No data
Q3 22
+75.8%
$-0.23vs$-0.95
Q3 22
No data
Q4 22
-392.9%
$-1.38vs$-0.28
Q4 22
No data
Q1 23
-143.2%
$-1.07vs$-0.44
Q1 23
No data
Q2 23
+23.7%
$-0.45vs$-0.59
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2023 | Jun 27, 2023 | $-0.59 | $-0.45 | +23.7% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | — | $-0.56 | — | — |
Q1 2023 | Feb 14, 2023 | $-0.44 | $-1.07 | -143.2% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-1.07 | — | — |
Q4 2022 | Nov 13, 2022 | $-0.28 | $-1.38 | -392.9% | ✗ MISS |
Q3 2022 | Sep 30, 2022 | — | $-1.38 | — | — |
Q3 2022 | Aug 15, 2022 | $-0.95 | $-0.23 | +75.8% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | — | $-1.16 | — | — |
Q2 2022 | Jun 28, 2022 | $-1.13 | $-1.20 | -6.2% | ✗ MISS |
Q1 2022 | Feb 14, 2022 | $-1.22 | $-1.30 | -6.6% | ✗ MISS |
Q4 2021 | Nov 14, 2021 | $-0.92 | $-1.15 | -25.0% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.65 | $-1.10 | -69.2% | ✗ MISS |
Q2 2021 | Jun 24, 2021 | $-0.65 | $-0.90 | -38.5% | ✗ MISS |
Q1 2021 | Feb 16, 2021 | $-0.55 | $-1.10 | -100.0% | ✗ MISS |
Q4 2020 | Dec 1, 2020 | — | $-0.07 | — | — |
Q4 2020 | Oct 24, 2020 | — | — | — | — |
Latest News
Loading news...
Frequently Asked Questions about REUN.TO
What is REUN.TO's current stock price?
Reunion Neuroscience Inc. (REUN.TO) is currently trading at $1.42 per share. The stock has moved -2.74% today.
What is the analyst price target for REUN.TO?
No analyst price targets are currently available for this stock.
What sector is Reunion Neuroscience Inc. in?
Reunion Neuroscience Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the TSX exchange.
What is REUN.TO's market cap?
Reunion Neuroscience Inc. has a market capitalization of $0.02 billion, making it a small-cap company.
Does REUN.TO pay dividends?
No, Reunion Neuroscience Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATE.TO
Antibe Therapeutics Inc.
$0.29
Mkt Cap: $0.0B
AYR-A.CN
Ayr Wellness Inc.
$0.15
Mkt Cap: $0.0B
EXM.CN
EXMceuticals Inc.
$0.20
Mkt Cap: $0.0B
IMCC.CN
IM Cannabis Corp.
$5.10
Mkt Cap: $0.0B
IMV.TO
IMV Inc.
$1.12
Mkt Cap: $0.0B
LXG.V
LexaGene Holdings Inc.
$0.10
Mkt Cap: $0.0B
NUMI.TO
Numinus Wellness Inc.
$0.05
Mkt Cap: $0.0B
RIV.CN
RIV Capital Inc.
$0.10
Mkt Cap: $0.0B
SGMD.V
Salona Global Medical Device Corporation
$0.22
Mkt Cap: $0.0B
TBP.TO
Tetra Bio-Pharma Inc.
$0.03
Mkt Cap: $0.0B
Explore stocks similar to REUN.TO for comparison